

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.

10/827,369

Confirmation No.: 4193

Applicant

Baldomero M. OLIVERA et al.

Filed

20 April 2004

TC/A.U.

1653

:

Examiner

Rosanne KOSSON

Attorney Docket No. :

2314-278

Customer No.

6449

Commissioner of Patents

P.O. Box 1450

Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

In the Office Action mailed 7 July 2006, the Examiner required restriction between 19 Groups. In response thereto, Applicants herewith elect Group I, claims 1-3 and 9-15 directed to a method for treating a cardiovascular disorder. Applicants further elect the sequence of SEQ ID NO:1. This election is made without traverse.

In introductory comments to the restriction, the Examiner asserted that SEQ ID NO:1 did not read on all of the peptides set forth in the claims. However, Applicants note that the Examiner is incorrect in this assertion because several of the residues in SEQ ID NO:1 can be lacking (e.g., Xaa, can be des-Xaa₁). Thus, SEQ ID NO:1 reads on all of the peptides set forth in the claims.

Respectfully submitted,

ROTHWELL, FIGG, ERNST & MANBECK, p.c.

Jeffrey L. Ihnen, Reg. No. 28,957

Attorney for Applicants

1425 K Street, N.W., Suite 800

Washington, D.C. 20005

Telephone No.: (202) 783-6040 Facsimile No.: (202) 783-6031